INM · InMed Pharmaceuticals Inc.

Summary

InMed Pharmaceuticals Inc. announced the wind down of BayMedica LLC's commercial operations due to impending prohibitions under H.R. 5371 effective November 12, 2026, with completion targeted prior to June 30, 2026, incurring approximately $550,000 in severance costs and $120,000 in additional expenditures. Post-wind down, the Company will focus exclusively on pharmaceutical development including INM-901 for Alzheimer's and INM-089 for dry AMD.

Key takeaways

• Board ratified wind down of BayMedica commercial operations on March 4, 2026
• BayMedica to substantially complete wind down by end of fiscal year June 30, 2026
• Expected severance and employee-related costs of $550,000
• Additional related expenditures of approximately $120,000 through June 30, 2026
• Future focus on INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration
• Pro forma cash and equivalents of $6,739,445 as of December 31, 2025